Thursday, November 21, 2024

08:00am  Registration | Check-in
09:30am – 11:30am  Advisory Boards Groups A & B | Elite Platinum only (up to 10 KOLs) First Come First Serve.
01:00pm – 03:00pm  Advisory Boards Groups C-D-E | Elite Diamond only (up to 20 KOLs)
04:30pm – 06:30pm  Advisory Boards Groups F-G-H | Elite Diamond only (up to 20 KOLs)
07:00pm – 09:00pm  VIP Reception with KOLs & Faculty Dinner 
Elite Diamond Sponsors

Friday, November 22, 2024

07:30am  Registration | Check-in
08:00am – 08:15am  Welcome & Introductions
Chairs: Marina Garassino, MD, Christine Lovly, MD, PhD, Luis E. Raez, MD, & Edgardo S. Santos, MD

Session I  
Lung Cancer Screening and Early Molecular Diagnosis
Moderator: Luis E. Raez, MD

08:15am – 08:25am  Establishing a Lung Cancer Screening Program
Karen Reckamp, MD

08:25am – 08:35am  How sensitive have to be a test to detect cancer and how about cancer interception and Methylation for Early Detection?
Christian Rolfo, MD
08:35am – 08:45am  Development of Incidental Pulmonary Nodule Programs (IPNs)  
Gerard Silvestri, MD

08:45am – 08:55am  Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Platforms  
Matthew Smeltzer, MD

08:55am – 09:30am  Q & A Session  
Moderator: Luis E. Raez, MD | Misty Shields, MD, PhD  
Panel: Reckamp, Rolfo, Shields, Silvestri, Smeltzer

09:30am – 10:30am  Educational Plated Breakfats (Non-CE)  
Presented by Elite Diamond & Elite Platinum Sponsors  
(First Come First Serve)  
Sponsored Program | Room 1  
Sponsored Program | Room 2  
Sponsored Program | Room 3

10:30am – 10:45am  Coffee Break | Visit Industry Connections

Session II  
Early-Stage Resectable Lung Cancer  
Moderator: Mark Socinski, MD

10:45am – 11:45am  
10:45am – 10:55am  What is the Best Way to Assess Complete Pathologic Response?  
Lynnette Scholl, MD

10:55am – 11:05am  Perioperative Chemo/Immunotherapy and Surgical Outcomes.  
Jay M. Lee, MD

11:05am – 11:25am  Debate: Is Perioperative Immunotherapy the New Standard of Care?  
Yes: Tina Cascone, MD  
No: Hossein Borghaei, DO

11:25am – 11:35am  How Can We Characterize Those Patients Who Need Adjuvant Treatment?  
David Gandara, MD

11:35am – 11:45am  Q & A Session  
Moderator: Mark Socinski
Panel: Borghaei, Bradley, Cascone, Gandara, Lee, Reckamp, Scholl,

Session III  
Early-Stage NSCLC-Case-Based Panel Discussion  
Moderator: Karen Kelly, MD  
5 min Presentation | 10 min Panel Discussion

11:45am – 12:00pm Case #1. Mary Jo Fidler, MD  
12:00pm – 12:15pm Case #2. Erminia Massarelli, MD  
12:15pm – 12:30pm Case #3. Hatim Husain, MD  
12:30pm – 12:45pm Case #4. Jason Porter, MD  
12:45pm – 12:50pm Wrap-up Session  
Panel: Carbone, Fidler, Husain, Massarelli, Porter, Vokes

Session IV  
Keynote Presentation  
12:50pm – 01:15pm Update Progress in Targeted Therapies for Early Stage NSCLC discussing Neoadjuvant and Adjuvant options. Lyudmila Bhazenova, MD

01:15pm- 01:20pm Moderator: Luis E. Raez, MD  
Questions and Answers

01:20pm – 02:20pm Educational Lunches (Non-CE)  
Elite Diamond & Platinum Sponsors  
Sponsored Program | Room 1  
Sponsored Program | Room 2  
Sponsored Program | Room 3

02:20pm – 02:35pm Break | Visit Industry Connections

Session V  
Locally Advanced NSCLC-Unresectable (Stage III)  
Moderator: Daniel Morgensztern, MD

02:35pm – 02:45pm Assessing Resectability in Stage III NSCLC Jessica Donington, MD

02:45pm – 02:55pm Combining immunotherapy with radiation for LANSCLC. Megan Daly, MD

02:55pm – 03:05pm Moving the Bar Beyond PACIFIC. What is the best consolidation therapy for people with actionable and non-actionable genes? Balaz Halmos, MD
Q & A Session
Moderator: Daniel Morgenzstern, MD | Rajat Thawani, MBBS
Panel: Donignton, Daly, Halmos, Iyengar, Langer, Thawani

Session VI
03:35pm – 04:40pm
Locally Advanced NSCLC-Unresectable; Case-Based Panel Discussion
Moderator: Corey Langer, MD

03:35pm – 03:45pm
Case #1. Localized Advanced NSCLC w Driver Mutation
Raja Mudad, MD

03:45pm – 03:55pm
Case #2. Localized Advanced NSCLC w/o Driver Mutation
Misty Shields, MD

03:55pm – 04:05pm
Case #3. Localized Advanced NSCLC w PDL-1 No Expression
Wade Iams, MD

04:05pm – 04:15pm
Case #4. Localized Advanced NSCLC w Driver Mut (no EGFR/no ALK)
Kim Chul, MD

04:15pm – 04:40pm
Wrap-up Session
Moderator: Corey Langer, MD
Panel: Bradley, Chul, Iams, Massarelli, Mudad, Shields, Simon, Spigel

04:40pm – 04:45pm
Meeting Adjourns | Day 1
Luis E. Raez, MD

04:50pm – 06:50pm
Advisory Boards Groups I-J-K-L | Elite Platinum (up to 10 KOLs)

07:00pm – 09:00pm
VIP Reception with KOLs & Faculty Dinner
Elite Diamond Sponsors

Saturday, November 23, 2024

7:30am
Registration | Check-in

08:00am – 08:05am
Welcome & Introductions
Moderators:
Marina Garassino, MD and Christine Lovly, MD, PhD
Session VII
Small Cell Lung Cancer (SCLC)
Moderator: Paul Bunn, MD

08:05am – 09:20am

08:05am – 08:15am
Advances in Biomarkers for SCLC
Lauren Byers, MD

08:15am – 08:25am
SCLC: Where Are We At?
Catherine Meador, MD

08:25am – 08:35am
SCLC: Where Are We Going?
Charles Rudin, MD

08:35am – 08:45am
Role of Radiation Therapy in SCLC
Puneeth Iyengar, MD

09:05am – 09:20am
Q & A Session
Moderator: Paul Bunn, MD | Noura Choudry, MD
Panel: Byers, Choudry, Hirsch, Iyengar, Meador, Rudin

09:20am – 10:20am
Educational Plated Breakfasts (Non-CE)
Presented by Diamond & Platinum Sponsors
Sponsored Program | Room 1
Sponsored Program | Room 2
Sponsored Program | Room 3

10:20am – 10:35am
Break | Visit Industry Connections

Session VIII
Metastastic NSCLC with Genomic Alterations-
Case-Based Panel Discussion
Moderator: Christine Lovly, MD, PHD

10:35am – 11:40am

10:35am – 10:45am
Case #1. EGFR First Line Therapy
Xiuning Le, MD

10:45am – 10:55am
Case #2. Progression after Third Generation EGFR TKI or Other Therapies
Jonathan Riess, MD

10:55am – 11:05am
Case #3. ALK First Line
Julia Rotow, MD

11:05am – 11:15am
Case #4. Progressing on ALK TKI and Acquired Resistance on ALK Domain
Ibiagy Dagogo-Jack, MD
11:15am – 11:25am  Case #5. Progressing on ALK TKI with Acquired Resistance in an Alternative Pathway
Erminia Massarelli, MD

11:25am – 11:35am  Case #6. K-Ras other than G12C after First Line Therapy
Kim Chul, MD

11:35am – 11:40am  Wrap-up Session
Moderator: Christine Lovly, MD, PhD
Panel: Chul, Dagogo-Jack, Heymach, Hirsch, Le, Massarelli, Ou, Riess, Rotow

Session IX
11:40am – 12:45pm  Metastasic NSCLC with Genomic Alterations-
Case-Based Panel Discussion
Moderator: Edgardo Santos, MD

11:40am – 11:50am  Case #1. ROS1 First Line or At Progression
Justin Gainor, MD

11:50am -12:00pm  Case #2. RET First Line or a Progression Case
Alexander Drilon, MD

12:00pm – 12:10pm  Case #3. MET First Line or a Progression Case
Deborah Doroshaw, MD

12:10pm – 12:20pm  Case #4. Her2 Mutation First Line or a Progression Case
Stephen Liu, MD

12:20pm – 12:30pm  Case #5. B-RAF No V600E First Line or At Progression
Millie Das, MD

12:30pm – 12:40pm  Case #6. NTRK First Line
Mary Jo Fidler, MD

12:40pm – 12:45pm  Wrap-up Session
Moderator: Edgardo Santos, MD
Panel: Aggarwal, Baik, Doroshaw, Drilon, Fidler, Gainor, Liu, Salgia

Session X
12:45pm – 01:10pm  Keynote Presentation
The Era of Antibody-Drug Conjugates (ADCs) and Bi-
Specifics
Speaker: Jyoti Patel, MD

01:10pm – 01:15 pm  Moderator: Marina Garassino, MD
Question and Answers
01:15pm – 02:15pm  Educational Lunches (Non-CE)
   Presented by Diamond & Platinum Sponsors
   Sponsored Program | Room 1
   Sponsored Program | Room 2
   Sponsored Program | Room 3

Session XI
02:20pm – 03:20pm  Drug Development Forum | Pipeline Presentations in Lung Cancer (Non-CE)
   Moderator: Edgardo Santos, MD
   10 min each | Presented by Elite Diamond Sponsors
   Diamond Sponsor A
   Diamond Sponsor B
   Diamond Sponsor C
   Diamond Sponsor D
   Diamond Sponsor E
   Diamond Sponsor F

03:20pm – 03:30pm  Break | Visit Industry Connections

Session XII
03:30pm – 04:35pm  Metastastic NSCLC with Genomic Alterations
   Moderator: Cristina Baik, MD
   03:30pm – 03:40pm  Developing of Resistance to KRAS Inhibitors
                      Matthew Gubens, MD

                     03:40pm – 03:50pm  STK11, KEAP and TP53 as Co-Mutations with Bad Prognosis is there a Predictive Role?
                      Ferdinando Skoulidis, MD

                     03:50pm – 04:00pm  Exon 20 insertions what will be the ideal therapy?
                      Zosia Piotrowska, MD

                     04:00pm – 04:10pm  BRAF and NTRK inhibitors in NSCLC
                      Julie Brahmer, MD

                     04:10pm - 04:35pm  Moderator: Cristina Baik, MD
                      Panel: Brahmer, Gubbens, Piotrowska, Skoulidis

Session XIII
04:35pm – 05:55pm  Metastastic NSCLC without Genomic Alterations-
                    Case-Based Panel Discussion
   Moderator: Marina Garassino, MD
   04:35pm – 04:45pm  Case #1. Never Smoker without An Actionable Mutation
                      Tejas Patil, MD
04:45pm – 04:55pm  Case #2. Second Line Therapy after Immunotherapy or Chemo/Immunotherapy in Squamous Cell Carcinoma
Deborah Doroshaw, MD

04:55pm – 05:05pm  Case #3. First Line Immunotherapy with STK11 or KEAP1 mutations and PDL-1 >50% Adenocarcinoma
Biagio Ricciuti, MD

05:05pm – 05:15pm  Case #4. First Line Immunotherapy with with STK11 or KEAP1 mutations and PDL-1 0% Adenocarcinoma
Nagla Karim, MD

05:15pm – 05:25pm  Case #5. First Line Immunotherapy with Squamous histology and PDL-1 0%
Jorge Gomez, MD

05:25pm – 05:35pm  Case #6. First Line with Squamous histology and asymptomatic (1-2 subcentimeter lesions) in the brain, and PDL-1 35% (1-49%)
Sonam Puri, MD

05:35pm – 05:45pm  Case #7. Second-line After chemo/Immunotherapy and on Maintenance IO
Joshua Reuss, MD

05:45pm – 05:55pm  Wrap-up Session
Moderator: Marina Garassino, MD
Panel: Cascone, Doroshaw, Gadgeel, Gomez, Karim, Patil, Puri, Reuss, Ricciuti, Simon, Spiegel

05:55pm – 06:00pm  Meeting Adjourns | Day 2
Christine Lovly, MD, PhD

06:00pm – 7:30pm  Sundowner Reception with KOLs
Elite Platinum & Gold Sponsors

08:00pm – 10:00pm  Faculty Dinner

Sunday, November 24, 2024

07:00am – 09:00am  Farewell “Grab and Go” Breakfast for KOLs
Location: Lobby Area

07:00am – 09:00am  Post-Conference Advisory Boards or SWOTs